Status:
COMPLETED
Survival Nomogram for Patients With Thymic Carcinoma
Lead Sponsor:
Weijie Ye
Conditions:
Thymic Carcinoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients. Method A t...
Eligibility Criteria
Inclusion
- The diagnosis of TC in patients should be confirmed through endoscopic tumor biopsy or surgery to obtain tumor tissue for pathological confirmation under light microscope, and even further confirmed through immunohistochemical staining.
- Patients should accept surgery and obtain complete postoperative pathological reports in order to assess Masaoka-Koga staging.
- Patients who accepted surgery should be followed up at least six months or reached the endpoint event.
Exclusion
- The patient had two types of primary tumors concurrently including TC.
- The tumor in the thymus was not primary but metastatic, having originated from a different primary site.
- The patient did not obtain a complete pathological report after surgery.
Key Trial Info
Start Date :
July 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2025
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT07179341
Start Date
July 9 2024
End Date
August 1 2025
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China
Guangzhou, Guangdong, China